Allakos Inc
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California. Show More...
-
Website https://www.allakos.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 0.33 USD
-
Last Updated 14-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -0.52 -0.71 -2.2 -1.89 -1.99 Dividends USD Payout Ratio % * Shares Mil 33.0 33.0 20.0 45.0 47.0 Book Value Per Share * USD 4.65 10.57 9.8 Free Cash Flow Per Share * USD -0.89 -1.38 Return on Assets % -120.63 -46.54 -31.29 -24.11 -26.7 Financial Leverage (Average) 1.04 1.04 1.05 Return on Equity % -69.54 -25.12 -28.31 Return on Invested Capital % -69.4 -25.1 -27.59 Interest Coverage Current Ratio 5.35 30.89 34.55 38.27 33.75 Quick Ratio 5.29 30.52 34.04 37.97 33.47 Debt/Equity 0.02